- Home
- CNTY vs ELTX Comparison
CNTY vs ELTX Comparison
Compare CNTY & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTY | ELTX |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 63.3M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CNTY | ELTX |
|---|---|---|
| Price | $1.05 | $1.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.00 | ★ $18.00 |
| AVG Volume (30 Days) | 36.8K | ★ 338.0K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.31 | 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $430,529,000.00 | $2,301,000.00 |
| Revenue This Year | $7.17 | N/A |
| Revenue Next Year | $3.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.82 | N/A |
| 52 Week Low | $1.05 | $1.71 |
| 52 Week High | $2.73 | $16.00 |
Technical Indicators
Market Signals| Indicator | CNTY | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.97 | 24.02 |
| Support Level | N/A | $1.71 |
| Resistance Level | $1.33 | $3.32 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 6.67 | 26.26 |
Price Performance
Historical ComparisonAbout CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.